Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?

Georg Lenz1, Martin Dreyling

  • 1Lymphoma Section, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany. georg.lenz@med.uni-muenchen.de

Abstract

No abstract available in PubMed .

Related Concept Videos